HistoCyte – Lung Cancer controls

Gaining over 15,000 cases this 2024 and leading with the lowest survival rate for cancer types, lung cancer has been in the forefront of cancer cases in Australia. Biomarkers such ALK, ROS1, PD-L1, and BRAF are used in IHC and molecular laboratory techniques to identify specific types of lung cancer and guide targeted therapy.

Think Biocartis Idylla

WHEN TIME MATTERS. THINK BIOCARTIS IDYLLA*. YOUR BIOMARKER TEST RESULTS WITHIN 3 HOURS. The Idylla™ solution is a revolutionary, fully automated, real-time PCR based molecular testing system designed to offer results in a minimum amount of time.

Biocartis – Breast Cancer Portfolio

THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC. Biocartis is pleased to launch a new breast cancer portfolio: Idylla™ PIK3CA-AKT1 Mutation Assay, APIS Breast Cancer Subtyping Kit and APIS ESR1 Mutations Kit.

Biocartis Idylla™ GeneFusion Assay*

THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC. Within 180 minutes and with less than 2 minutes hands-on time, the fully automated Idylla™ GeneFusion cartridge detects ALK, ROS1, RET, NTRK1/2/3 rearrangements and MET exon 14 skipping in a single cartridge using only 1-3* FFPE tissue sections.